Characterization of Celecoxib-Loaded Solid Lipid Nanoparticles Formulated with Tristearin and Softisan 100
Purpose: To prepare solid lipid nanoparticles employing softisan 100 (SOFTI) or tristearin (TS) as solid lipid carriers for celecoxib (CXB) to overcome its dissolution challenge. Methods: The solid lipid nanoparticles (SLN) of CXB were prepared by ultrasonic melt-emulsification technique. SLN was ch...
Gespeichert in:
Veröffentlicht in: | Tropical journal of pharmaceutical research 2015-06, Vol.14 (2), p.205 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose: To prepare solid lipid nanoparticles employing softisan 100
(SOFTI) or tristearin (TS) as solid lipid carriers for celecoxib (CXB)
to overcome its dissolution challenge. Methods: The solid lipid
nanoparticles (SLN) of CXB were prepared by ultrasonic
melt-emulsification technique. SLN was characterized using differential
scanning calorimetry (DSC), Fourier transform infra spectroscopy
(FTIR), as well as for entrapment efficiency, particle size, zeta
potential and CXB release. Results: The SLN formulations exhibited high
CXB entrapment efficiency (91.6 % for SOFTI and 94.6 % for TS) while
mean particle size was 181.0 ± 4.6 and 346.3 ± 3.8 nm for
SOFTI and TS, respectively. The DSC thermograms showed the
disappearance of CXB peak due to its molecular distribution in the
lipid nanoparticles while FTIR spectra revealed physical interaction of
CXB with the tested lipids. The tendency of SOFTI to liberate CXB in 24
h was higher than that of TS (55.5 ± 1.07 vs 49.2 ± 2.94 %, p
< 0.05). Drug release was by non-Fickian mechanism. Conclusion:
Formulation of CXB in SLN using TS or SOFTI produces sustained drug
release delivery that can overcome the dissolution limitation of the
drug and thus, improve its therapeutic efficacy. |
---|---|
ISSN: | 1596-5996 1596-9827 |
DOI: | 10.4314/tjpr.v14i2.3 |